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Abstract
Uropathogenic Escherichia coli (UPEC) is the leading cause of community-acquired urinary tract infections (UTIs), with over
100 million UTIs occurring annually throughout the world. Increasing antimicrobial resistance among UPEC limits
ambulatory care options, delays effective treatment, and may increase overall morbidity and mortality from complications
such as urosepsis. The polysaccharide capsules of UPEC are an attractive target a therapeutic, based on their importance in
defense against the host immune responses; however, the large number of antigenic types has limited their incorporation
into vaccine development. The objective of this study was to identify small-molecule inhibitors of UPEC capsule biogenesis.
A large-scale screening effort entailing 338,740 compounds was conducted in a cell-based, phenotypic screen for inhibition
of capsule biogenesis in UPEC. The primary and concentration-response assays yielded 29 putative inhibitors of capsule
biogenesis, of which 6 were selected for further studies. Secondary confirmatory assays identified two highly active agents,
named DU003 and DU011, with 50% inhibitory concentrations of 1.0 mM and 0.69 mM, respectively. Confirmatory assays for
capsular antigen and biochemical measurement of capsular sugars verified the inhibitory action of both compounds and
demonstrated minimal toxicity and off-target effects. Serum sensitivity assays demonstrated that both compounds
produced significant bacterial death upon exposure to active human serum. DU011 administration in mice provided near
complete protection against a lethal systemic infection with the prototypic UPEC K1 isolate UTI89. This work has provided a
conceptually new class of molecules to combat UPEC infection, and future studies will establish the molecular basis for their
action along with efficacy in UTI and other UPEC infections.
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Introduction
Urinary tract infection (UTI) is the second leading infection in
humans [1] and the most common bacterial infection in the
ambulatory care setting in the United States, accounting for up to
8.6 million health care visits in 2007 [2]. Of the major causes of
UTIs, Escherichia coli (E. coli) is by far the primary etiology,
producing over 74.2% and 65.5% of UTIs in ambulatory and
hospitalized patients, respectively [3–5]. Twenty-five to forty
percent of first-time community-acquired UTIs are followed by
recurrences caused by the same clone of UPEC [3,6,7]. In
addition, E. coli also accounts for a significant proportion of sepsis
and meningitis of the young and old, with the infections
originating from the urinary tract or direct translocation from
the gut into the bloodstream [8]. With over 100 million UTIs
occurring annually throughout the world, including more than 10
million cases in U.S. adolescents and adults (per NIDDK data,
[9]), UPEC accounts for substantial medical costs and morbidity
worldwide.
Among all UTI cases, approximately 40-times more are treated
in the outpatient setting relative to inpatient care [7]. Rising
antibiotic resistance is a serious problem affecting the clinical
utility of the drugs commonly available for outpatient treatment of
UTIs (e.g., [10]). In the last decade, widespread use of antibiotics
has resulted in an increase in resistance of E. coli to commonly used
oral antibiotics. Whereas ampicillin and amoxicillin were once the
standard of treatment in uncomplicated UTI, the rates of
resistance are approaching 50% in certain parts of North America
[4]. Resistance rates have also dramatically increased among
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UPEC against trimethoprim-sulfamethaxozole (TMP-SMX), cur-
rently the first line therapy for outpatient treatment of UTI
[11,12]. Resistance to TMP-SMX has been emerging among
urinary tract isolates with rates in excess of 20% in some areas.
The Infectious Diseases Society of America (IDSA) now recom-
mends that in regions where resistance to TMP-SMX exceeds
20%, TMP-SMX should no longer be used for empirical therapy
[13]. Ciprofloxacin and other fluoroquinolones are used routinely,
but resistance to these agents is also on the rise (e.g., [14,15]), and
fluoroquinolone-resistant isolates of E. coli are often multidrug
resistant [16].
Almost all UTI treated in the community occur in individuals
with normal, robust immune responses to infection. Thus, a new
approach to therapy may be development and institution of UTI-
specific therapeutics that render microbes vulnerable to host
clearance mechanisms such as the innate immunity. Multiple
innate defense mechanisms are thought to participate in clearance
of bacteria from the urinary tract. A robust pro-inflammatory
cytokine response of IL-6 and IL-8 results from TLR4-LPS
stimulation [17–21]. Subsequently, neutrophils are recruited into
the urinary tract, producing pyuria. Complement levels increase
during inflammatory conditions in the urinary tract [22] and may
be an important mechanism of defense. Antimicrobial peptides
(AP), including the cationic 3–5 kDa peptides called defensins, are
abundant in the urine [23]. AP form pores in phospholipid
bilayers but require access to the bacterial outer membrane for
function [24]. Similar immune responses are activated and
effective in limiting the spread of UPEC from the urinary tract
to produce more disseminated disease.
The effectiveness of the innate immune response against
bacteria such as E. coli may, however, be severely hindered by
bacterial factors such as polysaccharide capsule. Capsules are well-
established virulence factors for a variety of pathogens and serve to
protect the cell from opsonophagocytosis and complement-
mediated killing [25,26]. In murine models, prior research has
demonstrated that the K capsule of E. coli is a preeminent
virulence determinant during UTI and bacteremia [27–29], as
well as critical for formation of intracellular bacterial communities
within the murine model of UTI. K capsules, also called K
antigens, are enveloping structures composed of acidic, high-
molecular-weight polysaccharides. Llobet et al. demonstrated that
highly acidic polysaccharide capsules of K. pneumoniae, P. aeruginosa,
and S. pneumoniae interact strongly with AP, acting as ‘‘sponges’’ to
sequester and neutralize the AP [30]. Furthermore in murine
models of UTI, we have found that K capsule contributes to
multiple aspects of UTI pathogenesis, including intracellular
replication [28], making inhibition of capsule biosynthesis a novel
target for attenuation of UPEC virulence.
Inhibiting K capsule production may sensitize the organism to
various components of the immune system. Proof-of-concept
evidence comes from the demonstration that injection of purified
K1 endosialiase, which enzymatically degrades the E. coli K1
capsule, prevented sepsis and meningitis after intraperitoneal
infection of neonatal rats with E. coli K1 [29]. However,
endosialidases may have limited therapeutic applications due to
their antigenicity, poor bioavailability, and potential action on
sialidated host proteins and lipids with shared linkages as the
capsular sialic acids (such as those present in neural tissues, [31]).
Furthermore, endosialidase has a very narrow biochemical target
range, limiting its application to specific K antigen types.
Chemical inhibition of K capsule production may achieve similar
therapeutic results without most of these limitations.
The genomic organization of Group 2 K capsules is highly
conserved with operons for assembly, export, and synthesis genes.
The synthesis genes vary encoding a variety of saccharide-
modifying enzymes that together change the polysaccharide
composition. The assembly and export genes are conserved and
encode for a multi-subunit export channel that spans the inner
membrane and periplasm to direct the polysaccharide capsule
through an outer membrane pore where the capsule is linked to
the outer membrane through end lipidation [32]. Similarly genetic
regulation of the Group 2 capsule operons is highly conserved with
two promoters solely driving transcription of all of the genes
needed for capsule expression [33–35]. Thus, small molecules
inhibiting the conserved aspects of the export channel or
regulation of its expression would be expected to block encapsu-
lation of a range of serotypically diverse Group 2 encapsulated
UPEC.
Here we extend our discovery process for new capsule small
molecule inhibitors. We previously described a facile assay for the
identification of such inhibitors that, when employed against a
modest number of bioactive small molecules, revealed an inhibitor
of K1 and K5 Group 2 capsule biogenesis designated as C7 [36].
We now describe the application of the assay to a large magnitude,
high-throughput screen for additional broad-spectrum capsule
inhibitors from which we found multiple new, chemically distinct,
and highly active molecules with promising therapeutic charac-
teristics.
Methods
Bacterial strains, phage, and growth conditions
All E. coli strains and phage used in the present study are listed
in Table 1. Unless otherwise indicated, bacteria were routinely
grown at 37uC in Luria-Bertani medium (LB) with shaking at
250 rpm. LB was supplemented with 1% dimethyl sulfoxide
(DMSO; Acros) with or without compound. Phage lysates were
prepared from 50 mL cultures of E. coli strains UTI89 (for K1F
phage), MG1655 (for T7 phage) or DS17 (for K5 phage) and
stored at 4uC over several drops of chloroform as described [37].
Screen for inhibitors of bacterial capsule biogenesis
Primary assay. The primary assay consisted of detection of
the presence and absence of the K1 capsule on the E. coli urinary
tract isolate UTI89 under growth conditions with compounds
from a large chemical library. The assay was conducted as
previously described [36] with the following modifications. The
primary assay was conducted in 1,536-well plate format. UTI89
DkpsM, an isogenic K1 capsule export mutant, was included as an
unencapsulated control. Tetracycline, 50 mM, was used as a
negative growth control. A 1:75 dilution of overnight cultures were
made in LB broth containing 0.5% DMSO, and 3 mL of this
culture was added to each plate well, and plates were incubated,
inverted, at 37uC for 2 hr. K1F phage stock was diluted 1:8 in LB
Broth containing 0.5% DMSO, and 1.5 mL of diluted phage (or
media only) was added to the pre-plated test compound wells and
appropriate control wells. The plates were centrifuged briefly, and
then were incubated, inverted, at 37uC for an additional 2 hr. To
increase sensitivity of detection of viable bacteria, 1 mL of a 1:2
dilution of AlamarBlue reagent (Invitrogen, #DAL1100) in LB
broth was added to each plate well. Alamar Blue, resazurin, is
converted in living cells to the fluorescent molecule, resorufin. The
plates were again centrifuged briefly, and then were further
incubated, inverted, at 37uC for 30 min. Resorufin fluorescence
was measured using excitation of 560 nm and emission of 590 nm,
as per the manufacturer’s recommendations.
Compounds from the NIH Molecular Libraries Small Molecule
Repository (MLSMR) were utilized in the primary assay. The
Inhibitors of Escherichia coli Capsule Biogenesis
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MLSMR collection of over 300,000 compounds generically
grouped into one of the following five categories: (a) specialty
sets, comprising bioactive compounds such as known drugs and
toxins, (b) non-commercial compounds, mainly from academic
labs, (c) targeted libraries, (d) natural products, and (e) diversity
compounds [38]. The MLSMR library covers a diverse sample of
the chemical space occupied by drugs and natural products, but
only narrowly represents combinatorial chemical space [39].
Compounds or vehicle control (DMSO) were diluted to a final well
concentration of 1:200 in assay media. Compounds (22.5 nL in
100% DMSO) were dispensed to assay plates using an Echo non-
contact dispenser (Labcyte). Compounds from the libraries were
added to the plates at a final concentration of 50 mM, before the
addition of bacteria or phage. Each compound was tested as a
single point, and ,1,200 compounds were tested per plate. A
positive hit was defined by the compound producing greater than
a 50% inhibition of K1F phage-induced lysis. Compound hits
were further confirmed using an optical density-based detection
method in a 96-well format as previously described [36].
Concentration-response to chemical inhibition. Con-
centration-response testing (concentration range = 0.58–
300 mM) was used to confirm and characterize the primary
screen hits, which was necessary to determine the number of
compounds advanced to secondary screens. Compounds were
plated in 1536-well microplates, and the concentration-
response efficacy assay was performed as described for the
primary screen, with the exception that each compound was
tested in duplicate at 10 concentration points starting from
300 mM and continuing to lower concentrations by 2-fold serial
dilutions. The strain UTI89 DkpsM, a K1 capsule export
mutant, was evaluated with the wild-type strain as a phage-
insensitive control (mimicking 100% capsule inhibition).
T7 phage counter assay. This secondary assay was
performed as previously described [36] and was used to distinguish
compounds with phage inhibitory effects from true polysaccharide
capsule inhibitors. T7 phage has a nearly identical genome to K1F
phage and thus a similar life cycle [40]; however, T7 phage does
not encode for an endosialidase, and its entry into E. coli is
inhibited by K capsules. Thus, the presence of a capsule inhibits
T7-mediated lysis [41]. In this assay, an increase in phage-induced
lysis correlates to a decrease in capsule formation. True inhibitors
of capsule yielded bacteria that were susceptible to T7 phage and
lysed within 2 hr of the addition of phage. However, compounds
inhibiting phage replication did not promote bacterial lysis. The
positive control molecule C7 (100 mM final well concentration)
was used in this screen.
Pan Assay Interference Compound (PAINS)
analysis. Groups of compound substructural features are
associated with compound biological promiscuity, and compounds
containing these features arise as frequent hits in biochemical high
throughput screens. These molecules have been described as
PAINS [42]. To determine if molecules of interest were within
chemical groups with known non-specific interference with the
bioassays, the structures for compounds DU001, DU003, DU005,
DU007, DU008, and DU011 were retrieved from PubChem and
saved in the Structure Data Format (SDF). The structures were
then compared to the SYBYL PAINS compounds library, to see
which, if any, of the compounds contain PAINS functional groups
[43].
Cytotoxicity. Testing was performed essentially as previously
described [36,44]. Concentration-response testing was performed
over a range 0.58–300 mM in a 386 well plate format. Bladder
carcinoma 5637 cells (ATCC HTB-9) were added to the
compounds, and 72 hrs later cell viability was measured using
CellTiter Glo (Promega). The 50% toxic concentration (TC50) was
determined and compared to the IC50 to calculate the therapeutic
index. Hyamine was used as a positive cytotoxic control. All wells
contained 0.5% DMSO.
Evaluation of off-target effects. Off target effects of lead
molecules of interest were evaluated using the LeadProfilingScreen
commercial assay at Eurofins Panlabs (Bothell, Washington).
Reference standards were run as an integral part of each assay to
ensure the validity of the results obtained. Assay results are
presented as the percent inhibition of specific binding or activity
(for n = 2 replicates) for the probe compound tested at a
concentration of 10 mM. Details regarding the individual assays
and methods are provided in File S1.
Orcinol assay for released capsule material. Orcinol
reactivity was used as a biochemical confirmation of altered
extracellular capsule after compound treatment. UTI89 or an
isogenic capsule mutant was grown in 100 mM of test compound
Table 1. Bacterial strains and phage used in this study.
Strain/phage Description or relevant genotype Reference
Bacterial strains
UTI89 K1 Escherichia coli cystitis isolate [49]
UTI89 DRegion I Region I (kps) K1 capsule mutant [28]
UTI89 DRegion II Region II (neu) K1 capsule synthesis mutant [28]
UTI89 DkpsM K1 capsule export mutant [28]
DS17 Escherichia coli K5 pyelonephritis isolate; K5 encapsulated, susceptible to K5 specific phage [50]
EV36 K-12/K1 hybrid produced by conjugation with an Hfr kps+ strain; K1
encapsulated, susceptible to K1-specific phage.
[51]
CFT073 K2 Escherichia coli urosepsis isolate [52]
536 K15 Escherichia coli urinary tract isolate [53]
Phage
T7 phage (T7Q) Inhibited by K1 capsule [54]
K1F phage (K1FQ) K1 capsule specific [55]
K5 phage (K5Q) K5 capsule specific [56]
doi:10.1371/journal.pone.0096054.t001
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or 1% DMSO. The assay was performed as previously described
[36]. The molecule C7 (100 mM final concentration) was used as a
positive control. The assay was performed 3 times with replicate
samples.
K1 antigen dot blot. K1 antigen was detected by dot blot
assays of culture extracts probed with anti-K1 H46 serum. The
assay was performed as previously described [36]. The experiment
was repeated twice with similar results, and a representative dot
blot is shown.
Visualization of capsule using Alcian blue
staining. Overnight cultures of clinical E. coli strains were
diluted 1:100 in the presence of 1% DMSO or 100 mM DU011.
Cultures were grown for ,6 hrs (OD600 = 1.2) at 37uC. Samples
were centrifuged at 13,200 RPM for 5 min. The medium was
removed and the cells were resuspended in 500 mL of Tris-Acetate
(pH 5) and shaken for 1 hr at 37uC. Samples were re-centrifuged,
and the supernatant was concentrated ,100 fold in Amicon 3K
microconcentrators. The preparations were separated on a 7.5%
SDS-PAGE gel and stained with 0.125% Alcian blue as previously
described [45].
K5 phage assay. This assay determined if compounds found
to be active in the K1F, T7, orcinol, and K1 antigen dot blot
secondary assays were able to also inhibit K5 capsule biogenesis.
The assay was performed in a method identical to the T7 assay test
[36]. E. coli strain DS17, a pyelonephritis clinical isolate expressing
a K5 capsule and susceptible to K5 phage (K5), was used as a K5
prototypic test strain. The degree of inhibition of phage-mediated
lysis was determined based on the absorbance (OD600).
Human serum sensitization by capsule inhibitor
treatment. Overnight cultures of UTI89 were diluted 1:100
and grown with or without 50 mM compound for approximately
1.5 hrs on a shaker at 37uC. Then 25 mL of anonymous, non-
identified, sterile filtered pooled human serum (purchased from
Equitech Bio) was added per 100 mL of growth media. This was
returned to the shaker for another 3 hrs, after which 20 mL of
5 mg/mL MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetra-
zolium bromide) was added. MTT is reduced to purple formazan
by bacterial reductase enzymes, thus measuring viable bacteria.
This was shaken for another 15 min at 37uC. The sample was
spun to remove the growth media, followed by two washes with
PBS. The formazan crystals were dissolved in 100 mL of DMSO
and measured at OD570.
Murine UPEC sepsis model and treatment with
DU011. Groups of five 6–7 week old C57BL/6NCr female
mice (purchased from Frederick National Laboratory for Cancer
Research) were injected subcutaneously twice daily with 100 mL of
1% DMSO (vehicle control) or DU011 (1 mg/ml) starting 12 hrs
prior to the intra peritoneal infection. Weights were recorded
twice daily to monitor health of the animals and tolerance to the
compound. Mice were challenged by intraperitoneal injection with
108 CFU of the indicated E. coli UTI89 in 100 mL of PBS. Briefly,
cultures were prepared by diluting overnight cultures (18 hrs)
1:100 into 3 mL of LB supplemented with 1% DMSO final or
100 mM DU011 (1% DMSO final). Shaken cultures were grown at
37uC for 6 hours to an OD600 of 1.2, and then cells were pelleted
and resuspended in 1 mL of PBS. Absorbance was adjusted to
OD600 of 0.8 in PBS, and the cultures were then diluted 1:10 in
sterile PBS. Animals were also given an intraperitoneal dose of 1%
DMSO or DU011, in a site different than the administration of
bacteria, to ensure sufficient systemic delivery of drug. Animal
survival was assessed after 12 hours. Surviving mice were re-dosed
according to the treatment groups and continued to be monitored.
The experiment was concluded 48 hours post infection. The entire
experiment was repeated with similar results.
Throughout each experiment, animals were monitored each
6 hours from the time of infection until conclusion for serious
morbidity, including ruffled fur, decreased activity, slowed
respirations, and ill appearance. Animals were provided gel packs
for easily accessible additional hydration throughout the experi-
ments. When a moribund state was suspected or anticipated by
these criteria, animals were immediately euthanized to minimize
potential pain and/or suffering. Of the total animals with an
outcome categorized as death, the following numbers were
euthanized for terminal morbidity prior to septic death (eutha-
nized/total deaths): 3/10, no prior treatment; 3/5 prior chemical
treatment of bacteria alone; 0/2 prior chemical treatment of mice
alone. Euthanasia for all animals was through complete respiratory
cessation using the inhaled anesthetic isoflurane followed by
secondary assurance of death using bilateral thoracotomy. All
animal experiments were conducted with prior approval from the
Institutional Animal Care and Use Committee of Duke University.
Statistical analyses
Results were calculated as averages and standard deviations of
the means using the Graph Pad Prism 5 software package (San
Diego, CA). Nonparametric t-tests were used for statistical analysis
of data and calculation of p-values using Graph Pad Prism 5 or
Graph Pad online calculators. Significant differences are high-
lighted with a single asterisk when the p value is less than 0.05,
with two asterisks when the p value is less than 0.01, and three
asterisks when the p value is less than 0.001.
Results
Primary screen for novel capsule inhibitors
Our initial screen of 2,195 compounds from the Developmental
Therapeutics Program at the National Cancer Institute success-
fully identified a small-molecule inhibitor of uropathogenic E. coli
Group 2 capsule biogenesis. We described this compound, termed
C7, in a previous report as proof-of-principle that small-molecule
inhibition of capsule biogenesis is possible and that these novel
anti-infectives can block encapsulation and attenuate a pathogen
through exposure to host innate immune factors [36]. Based on
this proof-of-concept, the primary assay was adapted to a 1,536-
well format with the modifications for high-throughput screening
necessary to search for additional active molecules in significantly
larger chemical repositories. The K1 encapsulated strain of
uropathogenic E. coli UTI89 was grown in a 1,536-well plate
format in the presence of 50 mM compounds. After an initial
growth step, K1F phage specific for K1 capsule was added.
Compounds with no effect on capsule biogenesis allowed the
growth of organisms with an intact capsule that were subsequently
lysed by the addition of the K1F phage. However, those
compounds that presumably inhibited capsule biogenesis and
allowed growth of the unencapsulated organism did not lyse with
the addition of the K1F phage. These compounds were then
selected for a secondary assay.
In total, 338,740 compounds were screened in the primary
assay (using K1F phage), and 1,767 compounds associated with
resistance to phage lysis (0.52% of total) were tested in
concentration-response format. Of these, 29 compounds passed
concentration-response validation (1.6% of compounds passing the
primary screen), and 6 were selected after demonstrating high
activity in the T7 phage secondary assay, the reciprocal phage
assay in which chemical unencapsulation sensitizes a K1:K12
hybrid strain, EV36, to lysis by the T7 phage. Concentration
response curves for 2 of these compounds are shown in Figure 1.
Compounds with promising chemical structures and low cytotox-
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icity to cultured bladder epithelial cells were selected for further
characterization. As seen in Table 2, the activity of these
compound hits in primary and secondary assays is consistent with
molecules with capsule inhibitory action. Cytotoxicity data further
indicate that these molecules are non-toxic to cultured bladder
epithelial cells. Furthermore, these new compounds, designated
DU001, DU003, DU005, DU007, DU008, and DU011, are more
active in the phage assays than the original proof-of-concept agent
C7, with IC50 values in the micromolar range.
Identification of potential Pan Assay Interference
Compounds (PAINS) among capsule inhibitor hits
A number of compound substructural features have been
identified that are associated with compound biological promis-
cuity, and, in particular, compounds with certain structural
features appear as frequent hits in biochemical high throughput
screens. These molecules have been described as PAINS {Merging
Citations}. Although PAINS may remain useful hits, we sought to
prioritize the compound hits DU001, DU003, DU005, DU007,
DU008, and DU011 by identifying and removing PAINS-like
molecules from our prioritization. Three of the six most active and
selective compound hits, DU005, DU007, and DU008, are
considered PAINS [40], and thus were not submitted for
additional biological characterization.
Confirmation of primary hits and spectrum of activity
Compounds were further characterized by determining bio-
chemically the level of surface capsule upon compound treatment
of a wild-type K1 encapsulated UPEC strain. We used mild-acid
to release capsule from cultures of UTI89 grown in the presence of
100 mM compound. We then used the orcinol reagent to quantify
the amount of released material. As shown in Figure 2A, orcinol
reactivity as % of wild-type for compound treatment indicates that
cultures treated with capsule inhibitors had decreased surface
reactive material, similar to levels observed for capsule synthesis
and assembly mutants.
As another independent measure of capsule inhibition by the
DU compounds, K1 antigen was evaluated using whole-cell dot
blots with anti-K1 serum. In all cases, treatment with these
molecules reduced reactivity to levels resembling those of genetic
capsule mutants (Figure 2B). The combined results from the
phage, orcinol, and immune-dot blots demonstrate that these
molecules inhibit normal capsule production and assembly,
significantly reducing the amount of surface assembled capsule.
A major consideration was whether the inhibitors of K1
encapsulation were also able to inhibit the production of other
important E. coli Group 2 capsule types. To confirm the range of
activity, we first demonstrated that treatment with each of
confirmed inhibitory molecules also inhibited K5 phage infection
of a K5 capsule-expressing strain, DS17 (Figure 3A). We next
determined if leading capsule inhibitors would also inhibit the
production of capsule in non-K1 serotypes. Capsular material was
isolated from strains 536 (K15 serotype), CFT073 (K2 serotype)
and DS17 (K5 serotype), and UTI89 (K1 serotype) in the presence
and absence of capsule inhibitors. Capsule was isolated from the
same amount of bacteria after growth in vehicle or with inhibitor
DU011 (200 mM). Isolated material was separated on a polyacryl-
amide gel and stained with the cationic dye alcian blue. As shown
in Figure 3B, capsule was reduced in each strain following growth
with DU011, regardless of serotype. Although visibly reduced in
capsule after growth in DU011, the reduction in capsular material
from treated CFT073 appeared slightly less than the other
serotypes tested. A similar reduction in extracted capsule was also
seen with DU003 (data not shown).
Figure 1. Concentration-response inhibition of K1 and T7 phage-mediated cell lysis. K1 (A, C) and T7 (B, D) phage activity in E. coli strain
UTI89 or EV36 (K1:K-12 hybrid strain), respectively, following treatment with various concentrations of DU003 (A, B) or DU011 (C, D).
doi:10.1371/journal.pone.0096054.g001
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Chemical inhibition sensitized UPEC to serum-mediated
killing
Capsule offers protection against serum-mediated killing. In
order to test whether compound treatment of UPEC increased
serum-mediated killing, an in vitro serum resistance assay was used.
As shown in Figure 4, pooled human serum decreased the amount
of viable UPEC as measured by an MTT metabolic activity assay.
Treatment of UPEC with either 50 mM DU003 or DU011 further
increased serum-mediated killing, thus significantly reducing the
measurable bacteria as compared to DMSO treated cells
(p = 0.0067). This decrease was similar to the serum sensitivity
observed for a genetic capsule mutant (Dneu).
DU003 & DU011 are biologically selective
DU003 and DU011 were submitted to the Eurofins Panlabs
LeadProfilingScreen to assess off-target pharmacology [42]. Both
compounds were tested in duplicate at 10 mM concentration and
showed no significant activity across the panel of 68 targets (i.e., ,
32% inhibition for DU011 and ,30% inhibition for DU003,
except for one target, the norepinephrine transporter, for which
58% inhibition was observed; full data and assays are provided in
File S1). In review of PubChem data, DU011 (CID23602075) is
reported to have shown activity in only 21 of 467 (4.5%, as of
September 5, 2013) bioassays in which it was tested (assays
unrelated to the current project). Per PubChem, DU003
(CID18109210) is reported to have shown activity in only 5 of
427 (1.2%, as of September 5, 2013) bioassays in which it was
tested (assays unrelated to the current project). Together, these
results suggest that DU011 and DU003 are not biologically
promiscuous compounds.
Attenuation of E. coli disseminated infection by DU011
In order to test the ability of these compounds to prevent lethal
systemic E. coli infection in mice, we selected DU011 for animal
testing based on its favorable solubility, permeability, and plasma
and microsome stability profiles (Table 3). As shown in Figure 5A,
C57BL/6 mice were administered DU011 or 1% DMSO
12 hours prior to lethal challenge with 108 CFU of UPEC
UTI89 by intraperitoneal injection. All previously untreated mice
receiving non-pretreated bacteria were moribund or died within
24 hr post-infection. In contrast, pretreatment of the bacteria and
mice with DU011 conferred complete protection with 100%
survival for the duration of the experiments (48 hrs) and recovery
of pre-infection weights (Figure 5B), similar to the 100% survival of
animals administered UTI89 DRII, an unencapsulated isogenic
mutant (data not shown). Administration of subcutaneous DU011
and untreated UTI89 provided 80% survival with stabilization of
weights at the end of the experiment. Pre-treatment of bacteria
without pretreatment of the mice produced 50% survival with
ongoing weight loss among surviving animals. Mice tolerated
DU011 without evident side effects. These data indicate that
pretreatment of mice with DU011 was able to significantly reduce
mortality due to disseminated E. coli infection, demonstrating the
potency of polysaccharide inhibition in vivo.
Table 2. Structure, K1 and T7 phage activity, cytotoxicity, and selectivity of capsule inhibitor compounds.
Compound CID IC50 K1 phage (in mM) IC50 T7 phage (in mM) Cytotoxicity (CC50 in mM) Selectivity (CC50/IC50)
DU001 1247114 10.662.0 0.2660.18 .100 .9.4
DU003 18109210 1.3860.02 1.060.03 239689 183
DU005 24235566 26.161.57 1.5760.01 .100 .3.8
DU007 46254879 22.665.4 2.560.02 .100 4.4
DU008 4483668 3.360.76 0.5460.7 45.08 13.7
DU011 23602075 4.562.5 0.6960.78 51.6613.6 13.3
Values shown correspond to the average of at least 3 replicates 6 SEM. CID indicates the PubChem Compound Identification.
doi:10.1371/journal.pone.0096054.t002
Figure 2. Biochemical and immunologic verification of E. coli Group 2 capsule inhibition through small molecules. A) Orcinol reactivity
of capsular material released by mild acid treatment of cultures grown with 1% DMSO vehicle (UTI89 and genetic capsule mutants) or 100 mM C7,
DU001, DU003, DU005, DU007, DU008, or DU011. Data represent independent experiments performed in duplicate. Treatment of K1 strain UTI89 with
compounds reduces amount of orcinol-reactive polysaccharides on surface of bacteria by ,80%. B) Whole-cell anti-K1 dot blots of cultures of UTI89
or indicated genetic capsule mutants treated with 1% DMSO or 100 mM DU001, DU003, DU005, DU007, DU008, or DU011 indicate that treatment of
cultures with compounds reduces K1 reactive material to levels comparable to those of genetic capsule mutants. DRI and DRII indicate a complete
deletion of Region I of the capsule kps and Region II capsule neu loci, respectively.
doi:10.1371/journal.pone.0096054.g002
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Discussion
E. coli infections play a significant role in community-acquired
UTI with substantial morbidity and associated costs. With a
diminishing arsenal of antibiotics available for the treatment of
UTI, new therapeutics are in great demand. Anti-virulence agents
capable of specifically attenuating a pathogenic organism during
its infectious cycle hold great potential as they may spare the
microbiota in commensal niches.
Previous work in our lab and in others has highlighted the
importance of capsular polysaccharides in the pathogenesis of
uropathogenic E. coli [27–29]. Group 2 and 3 capsules are highly
Figure 3. Inhibitor treatment decreases capsule production in different pathogenic E. coli serotypes. A) K5 E. coli was grown in vehicle
or with different inhibitors (50 and 100 mM) and then challenged with K5 lytic phage, which results in cell death in the presence of capsule. Growth
was measured by absorbance at OD600. B) Capsular material was isolated from multiple strains grown with and without inhibitor DU011 (200 mM).
Capsule preparations were performed in at least 3 independent trials. A single representative image is shown.
doi:10.1371/journal.pone.0096054.g003
Figure 4. Capsule inhibitors sensitize UPEC K1 strain to serum-
mediated killing. E. coli UTI89 and genetic capsule mutants were
grown in the presence and absence of DU003 or DU011 at 50 mM and
exposed to human serum. Bacterial metabolism and viability was
measured using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazo-
lium bromide). UTI89 grown in the presence of 50 mM DU003 or DU011
were significantly more sensitive to pooled human serum compared to
control UTI89 (** p = 0.0067). This was similar to the serum sensitivity of
the capsule mutant UTI89 DRII. DRI and DRII indicate a complete
deletion of Region I of the capsule kps and Region II capsule neu loci,
respectively.
doi:10.1371/journal.pone.0096054.g004
Figure 5. DU011 protects mice against a lethal dose of K1 E.
coli. A) C57BL/6 mice were administered subcutaneous 1% DMSO
(control) or DU011 (100 mL of 1 mg/ml in 1% DMSO) 12 hours prior to
lethal intraperitoneal injection with 108 CFU of UTI89 prepared in media
containing 1% DMSO or DU011 (200 mM in 1% DMSO). Surviving
animals continued to receive DMSO or DU011 each 12 hours through
the course of the experiment, according to their groups (B) Weight was
monitored during DMSO and DU011 administration and after infection.
doi:10.1371/journal.pone.0096054.g005
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conserved and represent the predominant circulating capsule types
[46]. We have previously described the identification and
characterization of a novel agent designated C7 that is active
(IC50 between 12.5–25 mM), blocks the production of K1 and K5
capsule biogenesis, and lacks obvious toxicity to cultured bladder
epithelial cells [36]. We have since conducted a high-throughput
screen for additional broad-spectrum capsule inhibitors, finding
several structurally distinct and highly active new molecules with
promising therapeutic characteristics.
Herein, we described the initial identification and character-
ization of these new small molecules. This group of capsule
inhibitors features lower IC50 values and improved solubility,
permeability, and plasma and microsome stability profiles (Table 3;
File S2). We have demonstrated their activity in assays with
human serum (Figure 4). Most importantly, dosing of mice with
DU011 had no detectable adverse effects on the animals and
protected against a lethal E. coli systemic challenge (Figure 5). This
new approach may provide the basis for the next pre-clinical steps
to test these inhibitors as UTI-specific therapeutics that render
microbes vulnerable to host clearance mechanisms such as innate
immunity, enhancing the adaptive immune responses in the
process by allowing greater engagement of the immune system.
While dosing and delivery will need to be evaluated in future pre-
clinical pharmacokinetic and pharmacodynamics studies, we
believe these data highlight the potential use of capsule inhibitors
as specific anti-virulence therapeutics. The compounds listed in
Tables 2 and 3 are synthetically amenable lead compounds and
work is currently underway to improve upon their properties.
Synthesis of large lots of DU011 and other compound hits has
made animal testing possible as well as facilitated work on the
mechanism of action of these compounds. This will aid in the
identification of their biological target and will advance our
understanding of capsule biogenesis and regulation in E. coli and
other organisms with similarly conserved capsule loci. This could
lead to the attenuation of diverse encapsulated organisms sharing
similar capsule assembly and regulatory mechanisms. The
generation of novel highly active small-molecule inhibitors of
capsule biogenesis will also aid in our understanding of the role of
the innate and adaptive immune systems in control of encapsu-
lated bacterial pathogens during systemic infections. A better
understanding of how DU003, DU011 and others affect the
interaction of the bacterium with host immune responses will
significantly aid in the development better anti-infectives that not
only attenuate the organism, but also actively engage the host
immune system to promote clearance.
Supporting Information
File S1 Ricera LeadProfiling Screen Data Tables. Data
for screens of off target effects by DU003 and DU011 are
provided.
(PDF)
File S2 Experimental procedures for aqueous and LB
medium solubility, hepatic microsome stability, PAMPA
permeability, and plasma stability. Additional methodo-
logical details are provided for these assays.
(PDF)
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